About Tergene Biotech Limited
Data last updated: 24 December 2025
Tergene Biotech Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Aurobindo Pharma Ltd. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 07 March 2008, the company has been in operation for over 18 years.
Registered with ROC Hyderabad under CIN U24230TN2008PTC066737.
Capital: an authorised share capital of ₹47.5 Cr and a paid-up capital of ₹47.15 Cr. Formerly known as Tergene Biotech Private Limited. It is led by directors including Umesh Krishnamoorthy and Mosuvan Kuppusamy.
Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032.
As per the financials filed for FY 2025, the company reported a revenue of ₹8.94 Lakh, a decline of 98% compared to the previous year.
It operates as a subsidiary of Aurobindo Pharma Ltd.
The company is associated with 2 brands - Aurobindo Pharma, Tergene Biotech. As per MCA filings, the company has satisfied charges of ₹1.18 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website tergene.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media**************
-
Registered AddressGalaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Tergene Biotech Limited
Tergene Biotech Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24230TG2008PLC113178, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230TG2008PLC113178 | Current |
| U24230TN2008PTC066737 | Previous |
| U24230TG2008PTC113178 | Previous |
Associated Brands with Tergene Biotech Limited
Tergene Biotech Limited operates two associated brands: Aurobindo Pharma and Tergene Biotech. These brands represent Tergene Biotech Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Generic biocatalytic solutions are provided for pharmaceutical applications. | aurobindo.com | |
| Bio-conjugate technologies for bacterial vaccines and conjugates are developed. | tergene.com |
Competitors & Alternatives of Tergene Biotech Limited
Brands and companies operating in the same space as Tergene Biotech Limited include Biological E, Concord Biotech, BDR Pharmaceuticals Internationals and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Biological E
|
Vaccines and therapeutics for multiple diseases are developed and marketed. | Hyderabad, India, India | 1953 |
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Insmed
|
Developer of small molecule inhibitors for rare lung diseases | Bridgewater, United States, United States | 1999 |
Vaxart
|
Developer of therapeutic solutions for treating multiple infectious diseases | San Francisco, United States, United States | 2004 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Eligo Bioscience
|
In vivo gene editing technology is developed for microbiome modulation. | Paris, France, France | 2014 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Affinivax
|
Technology-based conjugate vaccines against infectious diseases are developed. | Cambridge, United States, United States | 2013 |
Business Activity of Tergene Biotech Limited
Tergene Biotech Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Tergene Biotech Limited
Tergene Biotech Limited is currently managed by 7 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Umesh Krishnamoorthy | Director | 28 Jun 2023 | 3 Years 0 Months | Current |
| Mosuvan Kuppusamy | Director | 07 Mar 2008 | 18 Years 4 Months | Current |
|
Sivakumaran Meenakshisunderam
Also directs:
Curateq Biologics Private Limited, Auro Peptides Limited, Apl Healthcare Limited and 2 more
|
Director | 01 Apr 2015 | 11 Years 3 Months | Current |
|
Kuppusamy Sathyan
Also directs:
Samies Technologies Private Limited
|
Director | 07 Mar 2008 | 18 Years 4 Months | Current |
|
Santhanam Subramanian
Also directs:
Eugia Steriles Private Limited, Aurobindo Pharma Ltd, Engenra Biologics Private Limited and 5 more
|
Director | 26 Aug 2016 | 9 Years 10 Months | Current |
Financials of Tergene Biotech Limited FY 2025 filings available
Tergene Biotech Limited reported revenue of ₹8.94 Lakh (down 98% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Tergene Biotech Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Aug 2012 | Biotechnology Industry Research Assistance Council | ₹1.18 Cr | Satisfied |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Tergene Biotech Limited
View historical data on people associated with Tergene Biotech Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Tergene Biotech Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Tergene Biotech Limited
GSTIN & GST Filing Data of Tergene Biotech Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Tergene Biotech Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Tergene Biotech Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Tergene Biotech Limited
MSME Payment Delays by Tergene Biotech Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Tergene Biotech Limited
Subsidiaries & Group Companies of Tergene Biotech Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Tergene Biotech Limited with ownership details.
MCA Filings & Documents of Tergene Biotech Limited
MCA Filings & Documents of Tergene Biotech Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Tergene Biotech Limited
Recent News on Tergene Biotech Limited
Frequently Asked Questions about Tergene Biotech Limited
Tergene Biotech Limited is an active public limited company in the life sciences sector based in Hyderabad, Telangana, India. It was incorporated on 07 March 2008 (18+ years old) and is registered under CIN U24230TG2008PLC113178.
Tergene Biotech Limited reported revenue of ₹8.94 Lakh for FY 2025 (down 98.00% YoY).
The current directors of Tergene Biotech Limited are:
- Umesh Krishnamoorthy
- Mosuvan Kuppusamy
- Sivakumaran Meenakshisunderam
- Vijayudu Gajulapalli
- Kuppusamy Sathyan
- Santhanam Subramanian
- Lonkari Sudhakar
The primary industry of Tergene Biotech Limited is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Tergene Biotech Limited can be reached at the registered office: Galaxy Floors 22 – 24 Plot No. 1 Survey No. 831 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032, or through the website tergene.com.
The authorised capital is ₹47.5 Cr, and the paid-up capital is ₹47.15 Cr.